SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Inovios FDA approval has lifted optimism about regulatory flexibility for rare-disease therapies, as traders position ahead of Capricors Nov. 22 FDA decision on deramiocel for Duchenne muscular dystrophy. The community is broadly bullish and discussing possible short covering, but claims of an approval leak remain speculation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros quarterly earnings report and outlook are the dominant focus, with traders weighing the companys preliminary revenue update against concerns about margins, cash flow, and whether forward guidance can sustain growth. Bullish traders expect strong results to support a rebound, while skeptics question management credibility and warn that a headline beat may not be enough to restore confidence.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is drawing attention ahead of its quarterly results, with traders focused on forward guidance and data-center demand for AI chips amid concerns raised by Intels weak outlook. Some expect strong results to support a rebound, while others worry that high valuation and recent tech-stock selloffs could weigh on the shares even if AMD beats expectations.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers quarterly results beat expectations and the company raised its full-year outlook, with traders pointing to growth in newer products and cost cuts as signs of a turnaround. The muted-to-negative share reaction has frustrated bulls, while skeptics cite flat overall revenue, declining COVID-related sales and looming patent expirations as reasons for caution.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals strong Rezdiffra growth and first profitable quarter are being overshadowed by a sharp selloff, with traders debating whether continued spending and the prospect of uneven near-term profitability outweigh the launch momentum. Some also question whether a whistleblower-retaliation lawsuit disclosed in the 10-Q is weighing on sentiment, though its role in the decline is uncertain.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

ANET is drawing attention ahead of its quarterly report, with traders focused on whether AI data-center networking demand and hyperscaler spending will support another strong result. Bulls see the pullback as a buying opportunity, while bears point to valuation, uncertain buildout schedules and volatile post-earnings trading.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv shares are rebounding after a third-quarter earnings beat, reaffirmed outlook, expanded cost-savings target and plans to resume share buybacks. Traders welcomed the update as a potential turnaround signal after a steep decline, while skeptics point to weak underlying growth and execution risks.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs quarterly results and decision to maintain its distribution are driving discussion, with traders noting that refinery-hedge losses contributed to the reported loss. The community is split between viewing the steady payout and CVR Energys refinery expansion as supportive, and worrying about IEPs losses and whether the distribution is sustainable.

Toast, Inc. engages in the development and provision of consumer payment application for restaurants. It offers terminals, kiosk, guest facing display, and system accessories. The firm also offers point of sale, reporting and analytics, online ordering and delivery, and kitchen display system. The company was founded by Jonathan Grimm, Aman Narang, and Stephen J. Fredette in December 2011 and is headquartered in Boston, MA.

Toast Inc - Ordinary Shares - Class A

Toast Inc

Toasts earnings are driving discussion: traders cite solid growth, profitability and raised guidance, but the shares sold off, prompting debate over whether expectations were higher and whether weakness in software stocks and AI-related concerns are weighing on sentiment. Some also point to the FTC lawsuit as a regulatory overhang.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm-election uncertainty is dominating discussion, with traders debating whether potential Republican losses could pressure the Trump-linked stock versus election-related optimism behind a relief bounce. Some also cite the TAE Technologies merger, while bearish posts raise concerns about dilution and the companys fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Equity

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.


Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.


Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.


iShares Trust - iShares MSCI USA Small-Cap ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026.</li><li>In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026.</li><li>In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well improvements are sustained on lowered dosing.</li></ul><p>Shares of Nektar Therapeutics (NKTR) jumped 10% on Thursday as investors await updates on its lead candidate, rezpegaldesleukin, being developed for autoimmune and inflammatory diseases.</p><p>The company has multiple near-term catalysts in place, some expected as early as this month. The stock posted its best day since April on Thursday. &nbsp; &nbsp;</p><h2 class="st-heading-2">NKTR’s Atopic Dermatitis Program</h2><p>The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026. The studies will test a specific dose given every two weeks for the first six months, followed by less frequent maintenance doses. They will include both patients who have never tried biologic medicines and those who have already used them. The goal is to gather the data needed for regulatory approval, with the first results expected around mid-2028.</p><h2 class="st-heading-2">Progress In Alopecia Areata</h2><p>In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026. These findings showed stronger responses in patients with severe disease. The company then said that it plans to meet with the FDA in the second quarter of 2026 to discuss plans for larger late-stage trials. Additional data from patients who stopped treatment will be released in the fourth quarter of this year.</p><h2 class="st-heading-2">Other Catalysts</h2><p>A longer-term update showing results from patients one year after they stopped taking the drug in the eczema study is expected in the first quarter of 2027. This could indicate whether the treatment provides lasting benefits even after therapy ends.</p><p>In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well the improvements are sustained on lowered dosing, and begin an early study in at least one new disease area beyond atopic dermatitis, alopecia areata, and Type 1 diabetes.</p><p>Nektar ended the first quarter of 2026 with more than one billion dollars in cash and investments after a public offering. This strong financial position gives the company runway well into 2028 to advance its lead drug without needing immediate new funding, it previously said.</p><h2 class="st-heading-2">How Did NKTR Retail Traders React?</h2><p>On Stocktwits, retail sentiment around NKTR stock jumped from 'bearish' to 'bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.</p><p>A Stocktwits user opined that momentum is building in NKTR stock.</p><p><stembedurl>https://www.stocktwits.com/FibonacciFortress/message/658228663</stembedurl></p><p>Another refuted the opinion, saying that there have not been many announcements from the company in recent weeks. “Quiet tape, fading catalysts, cold momentum,” they wrote.&nbsp;</p><p><stembedurl>https://www.stocktwits.com/FutureBulls/message/658197825</stembedurl></p><p><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> has gained 68% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-ends-higher-why-this-strategist-picks-biogen-over-other-biotech-peers/cZm7GYQR7jB">BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.

Current Price	$73.03
Prev Close	$72.87
Open	$72.99
Dividend Yield	N/A
50-Day Moving Average	$72.92
Beta	N/A
Avg. Volume	5,237.16
PE Ratio	N/A

52-Week High	$77.55
52-Week Low	$60.51
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

ISCB Fundamentals